Patents Assigned to Dispersol Technologies. LLC
  • Patent number: 10022385
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 17, 2018
    Assignees: Board of Regents, The University of Texas System, DisperSol Technologies, LLC
    Inventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. Dinunzio, Robert O. Williams, III
  • Publication number: 20170027911
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 2, 2017
    Applicant: Dispersol Technologies, LLC
    Inventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
  • Patent number: 9339440
    Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: May 17, 2016
    Assignees: Board of Regents, the University of Texas System, DisperSol Technologies, LLC
    Inventors: Chris Brough, James W. McGinity, Dave A. Miller, James C. DiNunzio, Robert O. Williams, III
  • Publication number: 20140039031
    Abstract: The present disclosure is directed to compositions and methods for formulating a pharmaceutical dosage form by forming a composition comprising acetyl-11-keto-?-boswellic acid, diindolylmethane, or curcumin with one or more pharmaceutically acceptable excipients for enhanced solubility to increase bioavailability and improve therapeutic efficacy. The composition can be processed by thermo-kinetic compounding along with conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 6, 2014
    Applicants: Dispersol Technologies. LLC, Board of Regents, The University of Texas System
    Inventors: Chris Brough, Robert O. Williams, III, James W. McGinity, Dave A. Miller, Justin Hughey, Ryan Bennett